Minireviews Open Access
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Radiol. Jul 28, 2025; 17(7): 107737
Published online Jul 28, 2025. doi: 10.4329/wjr.v17.i7.107737
Prophylactic occlusion balloon in placenta abnormalities: What every interventional radiologist needs to know
Lorenzo Steri, Department of Diagnostic Imaging, Ospedale Isola Tiberina Gemelli Isola, Rome 00186, Lazio, Italy
Pierluigi Barbieri, Alessandro Posa, Department of Diagnostic Imaging and Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome 00168, Lazio, Italy
Lavinia Gigante, Department of Woman, Child and Public Health, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome 00168, Lazio, Italy
ORCID number: Alessandro Posa (0000-0001-9617-3413).
Author contributions: Steri L and Posa A were responsible for conceptualization, data curation, and project administration; Steri L, Barbieri P, and Posa A were responsible for methodology; Gigante L and Posa A were responsible for visualization; Posa A was responsible for writing, reviewing, editing, and supervision; Steri L, Barbieri P, Gigante L, and Posa A were responsible for the investigation, resources, and writing the original draft; All authors read and agreed to the published version of the manuscript.
Conflict-of-interest statement: All authors declare no conflicts of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Alessandro Posa, MD, Department of Diagnostic Imaging and Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Largo Agostino Gemelli 8, Rome 00168, Lazio, Italy. alessandro.posa@policlinicogemelli.it
Received: March 31, 2025
Revised: April 21, 2025
Accepted: June 9, 2025
Published online: July 28, 2025
Processing time: 119 Days and 9.6 Hours

Abstract

Placenta abnormalities, which are collectively termed as placenta accreta spectrum (PAS), are increasing globally in the female population due to the large number of cesarean sections performed worldwide. PAS represents a rare but life-threatening occurrence that can lead to an increased risk of postpartum hemorrhage due to the abnormal infiltration of the chorionic villi in the uterine wall up to the adjacent structures. Performing a prophylactic occlusion of the iliac arteries for a brief amount of time using balloon-occlusion endovascular catheters in patients with PAS can help control unwanted blood losses during cesarean delivery or postpartum demolition surgery. The aim of this narrative minireview was to provide an overview of the aspects about prophylactic occlusion with endovascular balloons in patients with PAS and to analyze current evidence on this topic. In particular, this minireview included an overview of indications, patient selection, type of materials and devices used, technical advice and suggestions, clinical outcomes, and complications to give every interventional radiologist as well as every gynecologist and midwife all the information that is needed to address this particular condition in a safe and prompt manner.

Key Words: Placenta accreta; Balloon occlusion; Postpartum hemorrhage; Interventional radiology; Endovascular

Core Tip: Aim of this narrative minireview is to give a comprehensive overview on the use of prophylactic occlusion balloon, in preventing major blood losses in patients with placenta accreta spectrum, undergoing cesarean delivery or demolition surgery. The heterogeneity of the results of different studies on this topic, the extreme delicacy of the type of patients to be treated, often very young, are some of the key points on which there is a need to clarify the knowledge on the argument. As in many other pathologies, there is no univocal treatment validated for all patients, but the correct treatment must be tailored for each individual case, hence this work shows all the possible treatments available.



INTRODUCTION

Placenta abnormalities happen when the chorionic villi infiltrate the uterine wall too much. This abnormality is currently classified as a spectrum disorder, with three different conditions of abnormal placentation representing different grades of pathological invasiveness of the placenta[1,2]. Abnormal placentation, including placenta accreta, increta, and percreta, is collectively termed placenta accreta spectrum (PAS) and represents a major risk factor for life-threatening postpartum hemorrhage (PPH). These conditions occur as a consequence of a deep penetration of the chorionic villi in the decidua and in the uterine wall. When the chorionic elements surpass the basal layer of the decidua, the condition is known as placenta accreta. When the villi extend into the myometrium, the condition is termed placenta increta. When the villi surpass even the myometrium and reach the peritoneal serosa up to other organs, the condition is termed placenta percreta[3,4].

In the case of a prenatal diagnosis of placenta increta or percreta, there is the risk of a dangerous extension to the bladder or to adjacent structures, and demolition surgery (cesarean section plus hysterectomy and bladder and other structure resection) is mandatory[5,6]. The invasion of extrauterine structures and the risk of severe abdominal hemorrhage lead to the possibility of bladder and/or ureteral injuries while performing surgery. Therefore, it is recommended to deal with these situations by means of a preemptive elective intervention rather than approaching them in an emergency setting.

Prior to demolition surgery, an intra-arterial balloon catheter is used to perform a prophylactic occlusion balloon (POB)[7]. This method allows target arteries to be quickly occluded for a small amount of time soon after the delivery of the newborn, leading to a reduction of complications, particularly blood loss (BL). This minireview focused on the indications, materials, technique, complications, and outcomes of POB of the abdominal aorta (POB-AA), POB of common iliac arteries (POB-CIA) and POB of internal iliac arteries (POB-IIA) for the prevention of peripartum hemorrhage in pregnant females with placenta abnormalities.

EPIDEMIOLOGY AND PATHOPHYSIOLOGY

Placental abnormalities occur in around 0.03%-0.07% of pregnancies[8]. Abnormal placentation can occur in a focal spot of the placenta or across the entire placental insertion area. In the latter case, it is referred to as total placenta accreta, increta, or percreta. Some conditions may act as predisposing factors for the PAS (i.e. hysterotomy scars following previous cesarean section or previous myomectomy, hysteroscopic resection of uterine septa or fibroids, placenta insertion in the lower uterine segment also known as placenta previa, previous manual removal of the placenta, uterine curettages and/or revisions, assisted reproductive technology, induced abortions, endometritis sequelae, advanced multiparity, or previous use of intrauterine devices)[2,9].

Even though pathogenesis of PAS is still unknown, the most prevailing theory on its pathogenesis is correlated to the abovementioned predisposing factors as prior uterine surgery and subsequent uterine scars lead to a defective decidualization, facilitating the chorionic villi to abnormally adhere to the myometrium[2,10]. On the other hand, the occurrence of placental abnormalities in primigravid females without previous uterine procedures could be related to fibroids, adenomyosis, or other uterine pathology resulting in endometrial defects that lead to abnormal adherence of the chorionic villi[10].

The increase of cesarean sections in the last decades has led to an increase in the frequency of placental abnormalities. Placenta accreta is seen in around 4.1% and 13.3% of females with 1 and ≥ 2 previous cesarean deliveries, respectively[11]. The incidence is higher in females with placenta previa and previous history of cesarean section, ranging from 11.1% in females with 1 cesarean delivery to 60.0% in females with ≥ 3 previous cesarean deliveries[12]. This confirms that the hysterotomy scar represents a significant risk factor for pathological adherence of the placenta and that the risk increases with the number of previous cesarean sections[3,13].

CLINICAL PRESENTATION

The only way to timely address the risks related to the PAS is to perform prenatal diagnosis[5,14]. In routine clinical practice the differentiation between placenta accreta, increta, and percreta is almost always based on presumptive criteria and diagnostic imaging evaluation because the effective diagnosis can only be based on a histological evaluation of the uterus and the placenta that only occurs in the rare occurrence of postpartum hysterectomy or myometrial resection.

Histologically, in areas of placenta accreta, increta, or percreta, there is hypoplasia or absence of the decidua, determining a direct contact between the chorionic villi and the myometrium[15]. Pathological placental adherences do not have specific and pathognomonic clinical presentation as most are asymptomatic or have vague symptoms, like vaginal bleeding and abdominal cramping[16]. Premonitory prenatal signs include the evidence of microhematuria/macrohematuria in the absence of other potential causes, raising the suspicion of bladder involvement, or an abnormally elevated serum concentration of alpha-fetoprotein, human chorionic gonadotropin, and pregnancy-associated plasma protein A, provided that other causes have been excluded[17].

Even though placental abnormalities usually occur during the second half of the pregnancy, they may also present as early pregnancy complications, leading to spontaneous and induced abortions. Other clinical presentations in advanced cases can be with intra-abdominal hemorrhage or metrorrhagia as reported by Roeters et al[18]. They described a case of massive intraperitoneal hemorrhage at 14 weeks of gestational age caused by placenta percreta.

DIAGNOSIS

Accurate prenatal diagnosis is vital in order to anticipate complications and optimize perinatal outcomes. Ultrasound remains the first-line imaging modality due to its accessibility and elevated diagnostic performance. Some remarkable B-mode ultrasonographic features include the loss or thinning of the retroplacental hypoechoic zone, the irregularity of the uterine-bladder interface, and the presence of multiple intraplacental lacunae, which present a “moth-eaten” appearance. Taipale et al[19] demonstrated that grayscale ultrasound integrated with color-Doppler provides valuable diagnostic features for PAS, including turbulent blood flow within the lacunae and hypervascularity at the placental-myometrial interface, suggesting deep placental invasion. Color-Doppler evaluation also improves diagnostic sensitivity by identifying abnormal vascular patterns, such as bridging vessels and subplacental hypervascularity[19].

Another useful feature is uterine artery (UA) color-Doppler spectrum analysis. It has been explored as a predictive tool for adverse pregnancy outcomes, including placental insufficiency and hypertensive disorders. Schwarze et al[20] identified that abnormal UA waveforms, particularly the persistence of diastolic notching, were significantly associated with the development of preeclampsia and intrauterine growth restriction, indicating their potential role in early screening strategies.

In cases where the operator may find himself faced with cases of diagnostic doubt or unfavorable anatomy, especially those involving posterior placentation or maternal obesity, magnetic resonance imaging (MRI) plays a fundamental role in diagnosis. MRI enables better discrimination of the depth and morphology of placental invasion due to its superior contrast resolution. MRI findings suggestive of PAS include uterine bulging, dark intraplacental bands on T2-weighted images, and thinning or disruption of the myometrium. Taipale et al[19] reported that MRI effectively contributed to the prenatal diagnosis of placenta percreta, especially in cases where ultrasound findings were inconclusive.

Warshak et al[21] conducted a comparative study to evaluate the diagnostic performance of ultrasound vs MRI for placenta accreta. The findings showed that ultrasound had a sensitivity of 77% and specificity of 96%, while MRI achieved a sensitivity of 88% and specificity of 100%, indicating that MRI might be superior in accurate characterization of the extent of the placental invasion[21]. Moreover, the authors emphasized the role of combined imaging strategies and multidisciplinary planning in reducing the risks associated with PAS. The integration of B-Mode ultrasound, color-Doppler imaging, and MRI provides the necessary diagnostic approach for PAS disorders. Early detection facilitates appropriate peripartum planning, potentially mitigating the risks of massive hemorrhage and improving maternal and neonatal outcomes.

INDICATION TO TREAT

Cesarean hysterectomy remains the conventional treatment for managing PAS disorders. However, this procedure can be emotionally challenging, particularly for younger females or those wishing to preserve their fertility. While there are alternative approaches designed to remove the portion of the placenta invading the uterine wall, these techniques may lead to an increased risk of delayed bleeding and may necessitate a later hysterectomy[22,23]. Significant intraoperative BL may require massive transfusions, which in turn can cause complications such as fluid overload, acute respiratory distress syndrome, disseminated intravascular coagulation, and infections. Furthermore, surgical risks, including damage to the intestines, bladder, or ureters, are a concern[24].

Endovascular preventive management has emerged as an effective minimally invasive technique for controlling pelvic hemorrhage, with particular significance in obstetric settings such as placenta disorders. Endovascular arterial bleeding control may be performed with the use of (POB-AA), POB-CIA, or hypogastric arteries (POB-IIA), or even with UA embolization. Traditionally, POB serves to reduce the BL during the cesarean section in patients with PAS. The aim of the procedure is to bring an occlusion balloon to the target site and inflate it during the surgical intervention[25,26]. The procedure of POB is mainly performed to control bleeding, preserve the uterus, and reduce morbidity during planned hysterectomy[27].

MATERIALS

Procedural equipment to perform a safe POB in patients with PAS should include vascular sheaths [usually between 4-French (Fr) and 7-Fr, both long and short], 0.035 J-tip hydrophilic guidewires (at least 150-cm long), 4-Fr or 5-Fr diagnostic catheters with various tip shapes (the most commonly used are C1-2, multipurpose, S-W, SIM1-2), compliant or non-compliant occlusion-balloon catheters for iliac arteries or aorta. To reach a more distal vascular district it is a good option to use a microcatheter (< 3 Fr) and microguidewire (0.018 and 0.014) to prevent or at least reduce arterial spasms; however, this procedure usually does not require microcatheter and microguidewire use[28,29].

There is still no consensus on the type of occlusion balloon, in particular for deciding between compliant vs non-compliant balloons. Both have advantages and disadvantages due to their intrinsic properties and behavior[30]. Specifically, compliant balloons are softer and adapt to the vessel shape, reducing the risk of vessel wall damage (e.g., dissection, rupture); however, they usually need a larger introducer sheath[31]. On the other hand, non-compliant balloons, which are mainly used in angioplasty procedures, can fit in a smaller introducer vascular sheath and are designed to maintain their size and shape even when inflated with high pressure. This characteristic makes them good for this procedure as the balloon inflation is usually performed “blindly” in the operating theater without the aid of a C-arm. However, these balloons are less flexible, leading to a worse “matching” with the vessel lumen, increasing the risks of vessel wall damage[32]. Balloon choice should be made on a case-by-case basis, taking into account the site of occlusion, the vessel size, and associated patient vascular pathologies (i.e. vasculitides) or coagulopathies. When using non-compliant balloons, it is advised to manually inflate the balloon rather than using an inflation device.

In addition to the classical equipment for POB, it is recommended to always have on the shelf everything that could be needed to treat every type of complication. In particular, it is mandatory to have embolic materials, such as microparticles (250 µm and larger), gelfoam, coils, plugs, liquid embolic agents (i.e. cyanoacrylate, ethylene-vinyl alcohol-based embolics) as well as bare metal stents and covered stents. Percutaneous arterial closure devices can be useful and are usually used when the vascular access is over 7-Fr, although there is no limit. Closure devices can be avoided with vascular sheath up to 7-Fr, preferring manual compression[33].

PROCEDURAL TECHNIQUE

The aim of the POB is to bring the occlusion-balloon catheters to the target arteries (Figure 1). Procedural techniques of POB can vary between operators and different centers. The site of procedure (i.e. interventional radiology suite or surgery suite), fixed or mobile C-arm, operator (i.e. interventional radiologist, vascular surgeon, gynecologist), target artery (i.e. aorta, common iliac arteries, internal iliac arteries), starting moment of balloon inflation, and inflation and deflation time could be different based on site-specific needs. However, every gynecological arterial endovascular procedure should be performed in an angiographic (or hybrid) suite, with digital subtraction angiography and standard angiographic equipment[28,34].

Figure 1
Figure 1 Digital subtraction angiography. Balloon positioning between the right internal iliac artery and the common iliac artery in a 24-years-old pregnant female.

For POB procedures, digital subtraction angiography should be avoided in order to reduce fetal X-ray exposure according to the “as low as reasonably achievable” principles[35-37]. The median radiation dose reported by Dai et al[38] was less than 100 mGy. The use of X-rays can cause fetal teratogenic risk, but this risk does not increase if the radiation dose is inferior to 100 mGy as highlighted by the International Commission on Radiological Protection. A total of 21 out of 22 studies included in the meta-analysis by Dai et al[38] found radiation doses were inferior to 100 mGy.

Another important consideration is that the time of the procedure is less for POB-AA with respect to POB-CIA or POB-IIA, leading to a decreased radiation dose. The POB-AA procedure requires one vascular sheath and one balloon and no need to cross the abdominal bifurcation, whereas two vascular sheaths and two balloons are needed to cross the abdominal bifurcation and reach contralateral common/internal iliac arteries for POB-CIA and POB-IIA[27]. Also, ipsilateral vascular access saves time and thus radiation with respect to contralateral vascular access.

A sterile field must be prepared at the access points and excellent hand disinfection must be performed by the operators before the procedure. Gynecological interventional radiology procedures generally require dedicated anesthesiological assistance and hemodynamic support. The choice between general anesthesia and conscious sedation or local anesthesia should be based on site-specific procedural settings (i.e. procedure performed in the operating room just before the cesarean section vs procedure performed in the angio-suite)[28,39]. Fetal safety should always be taken into account when choosing the correct type of anesthesia. Every POB procedure needs a unilateral or bilateral retrograde common femoral artery access, obtained with the Seldinger technique and under ultrasound guidance. Then the appropriately sized vascular sheath can be placed[28,29].

During POB-AA, a unilateral retrograde common femoral artery access could be done, while during other types of POB a bilateral common femoral artery access is almost always necessary. Bilateral access can be ipsilateral in cases of POB-CIA (right access for right CIA, left access for left CIA) or can be contralateral in case of POB-IIA (right access for left IIA, left access for right IIA) performing an aorto-iliac cross-over[40]. Some authors perform bilateral common femoral access for POB-AA, while others also suggest the brachial approach for POB-IIA[41,42]. The brachial artery approach for balloon placement, leaving the femoral arteries free from the introducer sheath and the balloon catheters, could grant better and easier patient positioning in the gynecological position during delivery[42]. However, the approach from the upper arm has the drawback of a greater endovascular distance from the target site; moreover, due to the risks of access site complications, this approach should be performed only by experienced operators[43].

Under fluoroscopic guidance, the balloon catheter is brought over a hydrophilic guidewire in the target site and is inflated to evaluate the correct cessation of the blood flow. The occlusion balloon catheters can be placed in infra renal AA, CIA, IIA, or in the UA although studies have shown that occlusion of the infrarenal AA and IIA are the most widely practiced methods[25-27].

Several studies have focused on POB-AA. However, there is still debate on whether the aorta should be occluded and where. The aortic zone in which the occlusion balloon should be inflated is not clearly determined. Liu et al[44] reported that a zone-II occlusion (between celiac trunk and the most distal renal artery) significantly reduced the BL compared with a zone-III occlusion (below the renal arteries), without increasing harm if the occlusion was performed for no more than 15 min. However, even though a higher site of occlusion should lead to reduced BL during surgery, the ischemic adverse events could increase and involve a larger extension of tissues and organs[45]. Aortic occlusion could be suggested in selected cases in which the bleeding is believed to not be safely managed with a lower occlusion (i.e. CIA or IIA) due to the presence of arteries arising from “above” (such as the ovaria arteries) that are expected to greatly increase the BL during surgery.

Liu et al[27] did not find significant differences in the length of hospital stay, PPH, and time of cesarean section between POB-AA and POB-IIA. When the correct position of the balloon was demonstrated, the operator completely deflated it, and the patient was directly transferred to the operating room (if the procedure and the cesarean section were not performed in the same suite)[39]. Inflation of the occlusion-balloons in both IIA could be performed simultaneously with extraction of the fetus by the operator[39].

Kyozuka et al[29] reported the inflation of the balloon being performed immediately before the cesarean section, usually by an emergency physician or an obstetrician with experience in this interventional radiology procedure, with removal of the balloon catheters within the operating room. The operator could deflate the balloons at the end of the surgical intervention[39]. The time of inflation should be as short as possible, in particular for POB-AA, to reduce the possible complications, such as ischemic and vascular injury[27]. To reduce all the possible complications, some authors suggest intermittently inflating the balloons for a maximum duration of 40 min for POB-AA and 4 h for POB-IIA, with 10-15 min of deflation intervals to temporarily restore the blood supply[27,38].

Abouda et al[39] reported balloon inflation in case of POB-IIA not exceeding 60 min, while Huo et al[41] reported a mean time of 39.7 min for POB-AA. As reported by Yin et al[26], during POB-AA the balloon was inflated after cord clamping and in case of active bleeding for no longer than 10 min with a 1-min deflation interval. The balloon was left deflated if the bleeding became inactive[26]. After the surgical demolition, if a C-arm is available in the operating theatre, then the anterior branch of both IIA can be embolized with the use of gelfoam before deflating and removing the balloon catheters to prevent PPH[46].

A multidisciplinary approach involving obstetricians, anesthesiologists, and interventional radiologists is essential for optimal patient selection and procedural planning[1,2]. Occlusion balloon catheters should always be removed under fluoroscopic guidance.

COMPLICATIONS

Major complications include artery thrombosis (the most common balloon-related vascular complication; incidence 1%-5%) due to hypercoagulability of maternal blood, vascular intimal injury during insertion of the balloon catheter and the blocking time of balloon occlusion, artery dissection, groin hematoma, pseudoaneurysm, balloon migration, ischemic events of the lower limbs, reperfusion injury of tissues and organs, acute renal failure, and rarely artery rupture (even with death)[26,27,38,47]. Other studies included uterine necrosis, intrauterine synechiae, endometrial atrophy, secondary amenorrhea, and hypomenorrhea. Another possible complication is postembolization syndrome, inclusive of transient low abdominal pain or buttocks pain/numbness, and low-grade fever with/without leukocytosis. No significant difference was found in terms of complications between POB-AA and POB-IIA by Liu et al[27].

OUTCOME

The most important factors to consider as objectives of POB are BL, PPH, and peripartum hysterectomy. The latter after cesarean section could be performed as a life-saving treatment in patients with placenta previa (incidence: 5.28%-10.83%) due to PPH[47]. The most important causes of emergent peripartum hysterectomy are abnormal placentation (25.0%-73.3%), uterine atony (20.6%-43.0%), and uterine rupture (11.4%-45.5%). Yang et al[47] reported BL ranging from 271.4 mL to 2080.0 mL [mean cumulative BL: 1280 mL; 95% confidence interval (CI): 986-1574), of which the mean volume during cesarean section was 1225 mL (95%CI: 908-1543) and during cesarean hysterectomy was 1526 mL (95%CI: 1002-2050)[48].

Other outcomes we consider are length of hospital stay and RBC transfusions (RBCT). The POB significantly improves the rate of all these consequences[38,42,48-50]. Many studies[51-55] found a significant difference between patients treated with POB and those who were not[56-60] and specifically observed a significant difference in BL[61-65]. The most recent studies demonstrated good outcomes for POB in terms of BL and reducing complications during cesarean sections.

However, some authors suggest that POB could not prevent massive bleeding because during pregnancy a rich system of blood vessels is developed. The majority of studies available in the literature are non-randomized prospective and retrospective trials. There is a paucity of randomized controlled trials necessary to demonstrate the safety and efficacy of this procedure and to identify the type of patient with PAS disorders who can benefit most from the procedure. Moreover, the majority of available studies include a small cohort of patients[25].

For these reasons, the Eastern Cooperative Oncology Group and International Federation of Gynecology and Obstetrics guidelines show caution regarding the effectiveness of POB, in particular for the presence of numerous conflicting studies. On the other hand, many centers perform this procedure anyway with the results reported in this minireview[25,66].

The indications for POB-AA as opposed to POB-CIA or POB-IIA are still not clear, and this procedure should be evaluated by a multidisciplinary team composed of gynecologists, obstetricians, diagnostic and interventional radiologists, urologists, and vascular surgeons[45]. The great majority of available literature studies are focused on POB-AA. Various attempts have been made to occlude more and more cephalad vessels, starting from the IIA to the CIA up to the aorta[67]. BL and blood transfusion were significantly lower between POB-AA, POB-IIA, and POB-UA compared with the non-POB intervention, but the POB-AA group was the best treatment for reducing BL[38,41].

The BL estimated by Abouda et al[39] was from 2888 mL ± 863 mL in the control group and 1828 mL ± 324 mL in the POB-IIA group (P < 0.01), whereas the need for RBCT reduction was 10 ± 5 in the control group vs 4 ± 3 in the POB-IIA group (P < 0.01). Kyozuka et al[29] reported BL of 2312 g (95%CI: 49-4577) during cesarean section. The complete meta-analysis conducted by Liu et al[27] showed a significant difference in BL [mean difference (MD): -410.61 mL, 95%CI: -779.74 to -41.47, P < 0.001] compared between POB-AA vs POB-IIA. However, no statistically significant differences were noticed regarding RBCT volume, although it was less in the patients with POB-AA than POB-IIA (MD: -344.50 mL, 95%CI: -735.74 to 46.74, P = 0.08).

Other studies showed a clear reduction in the need for RBCT between the POB group and the non-POB group. However, in the meta-analysis by Nankali et al[68], the authors concluded that it cannot be established if POB-IIA gives advantage in term of RBCT[55,57,59] due to conflicting data between different studies[62,65,69]. The hysterectomy rate was lower in some studies[49,52,55,58], with a significant difference between the POB and non-POB groups[61,62]. The meta-analysis by Nankali et al[68] reported a hysterectomy rate for the POB-IIA group and non-POB group of 8.9% and 31.2%, respectively, and a difference in BL of 3.21 mL ± 0.38 mL.

The hysterectomy rate reported by Dai et al[38] was reduced in the POB-AA and POB-IIA groups compared with the non-POB group. Between the POB-IIA, POB-CIA, and POB-AA groups there was no significant difference observed; POB-CIA and POB-AA were the best options to reduce the hysterectomy rate. Between the POB-CIA and non-POB groups the difference was not statistically significant. The POB-AA and POB-IIA treatment groups had a notably lower RBCT compared with the non-POB group. However, no significant difference among the POB-IIA, POB-CIA, POB-AA, and POB-UA subgroups was noted by Dai et al[38], and the probability of reduced RBCT was higher in POB-AA[47]. The Lowest hysterectomy rates during cesarean section were associated with POB-AA in comparison with the non-POB group. However, it was similar with the POB-IIA group[27].

The risk of death is avoided in 15000 pregnancies per year globally through the use of blood products, hence RBCT is crucial in the management of patients with abnormal placentation[70]. The better effect in reducing RBCT was with POB-AA procedure with a mean reduction of 600 mL due to occlusion of collateral circulation during POB-AA[38]. Huo et al[41] estimated BL of 3167.65 mL ± 3255.71 mL, hysterectomy rate of 17.6%, and intensive care unit admission rate of 41.2%. Liu et al[27] reported non-significant differences in hysterectomy rates (odds ratio = 0.99, 95%CI: 0.22-4.44, P = 0.99] and UA embolization (odds ratio = 0.65, 95%CI: 0.36-1.18, P = 0.15) between POB-AA and POB-IIA, and they reported reduced duration of balloon dilatation in POB-AA than POB-IIA (MD: –5.34 min, 95%CI: -9.91 to -0.77, P = 0.02).

A secondary but important outcome is the X-ray dose exposition. The National Committee on Radiological Protection recommended a fetal radiation exposure value less than 150 mGy as a standard dose. However, Yin and Hu[26] showed in their study a value less than 20 mGy. Liu et al[27] reported a higher fetal radiation dose in POB-IIA than POB-AA (MD: -20.81 mGy, 95%CI: -31.84 to -9.78, P < 0.001).

From our best practical knowledge, however, POB-AA shows better outcomes in terms of complication rates. The choice of the POB procedure should be made by the interventional radiologist/vascular surgeon within the surgeon team. When the operator works in an interventional radiology suite, and the patient is brought to the surgical theater after the POB procedure, it is better to choose POB-IIA, as ischemic complications are less frequent. If the operator and obstetric surgeon work together in a hybrid suite, POB-AA could be the best option. The complication rate is low during POB, and in some studies no procedure-related complications were reported, despite a large number of procedures performed[26,29].

CONCLUSION

POB performed before a cesarean section in patients with PAS is useful to reduce surgery complications, in particular BL. Although widely used in many centers worldwide, it is not yet standard in most important gynecological guidelines due to some discordant results in literature. The choice between different devices, target artery, and technical execution is not standardized. More information about POB-AA is available in the literature in comparison to the other POB procedural variants. The rate of procedural complications is low. Real effectiveness and safety of this procedure should be evaluated through randomized studies to compare POB of different arteries, to standardize and optimize the procedural protocol, and to better manage the patients with placental abnormalities.

Footnotes

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Radiology, nuclear medicine and medical imaging

Country of origin: Italy

Peer-review report’s classification

Scientific Quality: Grade B, Grade C

Novelty: Grade A, Grade C

Creativity or Innovation: Grade B, Grade C

Scientific Significance: Grade B, Grade C

P-Reviewer: Nagamine T S-Editor: Luo ML L-Editor: Filipodia P-Editor: Lei YY

References
1.  Horgan R, Abuhamad A. Placenta Accreta Spectrum: Prenatal Diagnosis and Management. Obstet Gynecol Clin North Am. 2022;49:423-438.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 23]  [Reference Citation Analysis (0)]
2.  Liu X, Wang Y, Wu Y, Zeng J, Yuan X, Tong C, Qi H. What we know about placenta accreta spectrum (PAS). Eur J Obstet Gynecol Reprod Biol. 2021;259:81-89.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 5]  [Cited by in RCA: 35]  [Article Influence: 8.8]  [Reference Citation Analysis (0)]
3.  Hudon L, Belfort MA, Broome DR. Diagnosis and management of placenta percreta: a review. Obstet Gynecol Surv. 1998;53:509-517.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 176]  [Cited by in RCA: 153]  [Article Influence: 5.7]  [Reference Citation Analysis (0)]
4.  Oyelese Y, Smulian JC. Placenta previa, placenta accreta, and vasa previa. Obstet Gynecol. 2006;107:927-941.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 589]  [Cited by in RCA: 552]  [Article Influence: 29.1]  [Reference Citation Analysis (0)]
5.  Massiah N, Bhatti N, Bakour S, Downey G, Bambang K, Olufowobi O. Placenta praevia percreta with bladder invasion: an increasing obstetric catastrophe in modern practice. J Obstet Gynaecol. 2006;26:563-565.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 2]  [Article Influence: 0.1]  [Reference Citation Analysis (0)]
6.  Palacios Jaraquemada JM, Bruno CH. Accuracy of ultrasonography and magnetic resonance imaging in the diagnosis of placenta accreta. Obstet Gynecol. 2007;109:203; author reply 203.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 7]  [Cited by in RCA: 8]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
7.  Palacios-Jaraquemada JM. Value of prophylactic intraoperative uterine artery embolization in abnormal placentation. Fertil Steril. 2009;91:656-7; author reply 657.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 1]  [Reference Citation Analysis (0)]
8.  Jauniaux E, Grønbeck L, Bunce C, Langhoff-Roos J, Collins SL. Epidemiology of placenta previa accreta: a systematic review and meta-analysis. BMJ Open. 2019;9:e031193.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 62]  [Cited by in RCA: 106]  [Article Influence: 17.7]  [Reference Citation Analysis (0)]
9.  Sugai S, Yamawaki K, Sekizuka T, Haino K, Yoshihara K, Nishijima K. Pathologically diagnosed placenta accreta spectrum without placenta previa: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2023;5:101027.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 13]  [Cited by in RCA: 9]  [Article Influence: 4.5]  [Reference Citation Analysis (0)]
10.  Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol. 2018;218:75-87.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 273]  [Cited by in RCA: 441]  [Article Influence: 63.0]  [Reference Citation Analysis (0)]
11.  Jauniaux E, Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;217:27-36.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 142]  [Cited by in RCA: 191]  [Article Influence: 23.9]  [Reference Citation Analysis (0)]
12.  Marshall NE, Fu R, Guise JM. Impact of multiple cesarean deliveries on maternal morbidity: a systematic review. Am J Obstet Gynecol. 2011;205:262.e1-262.e8.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 318]  [Cited by in RCA: 267]  [Article Influence: 19.1]  [Reference Citation Analysis (0)]
13.  Usta IM, Hobeika EM, Musa AA, Gabriel GE, Nassar AH. Placenta previa-accreta: risk factors and complications. Am J Obstet Gynecol. 2005;193:1045-1049.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 243]  [Cited by in RCA: 256]  [Article Influence: 12.8]  [Reference Citation Analysis (0)]
14.  Palacios-Jaraquemada JM. Diagnosis and management of placenta accreta. Best Pract Res Clin Obstet Gynaecol. 2008;22:1133-1148.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 66]  [Cited by in RCA: 65]  [Article Influence: 3.8]  [Reference Citation Analysis (0)]
15.  Timor-Tritsch IE, Monteagudo A, Cali G, Palacios-Jaraquemada JM, Maymon R, Arslan AA, Patil N, Popiolek D, Mittal KR. Cesarean scar pregnancy and early placenta accreta share common histology. Ultrasound Obstet Gynecol. 2014;43:383-395.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 149]  [Cited by in RCA: 157]  [Article Influence: 14.3]  [Reference Citation Analysis (0)]
16.  Berkley EM, Abuhamad A. Imaging of Placenta Accreta Spectrum. Clin Obstet Gynecol. 2018;61:755-765.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 11]  [Cited by in RCA: 20]  [Article Influence: 2.9]  [Reference Citation Analysis (0)]
17.  Bartels HC, Postle JD, Downey P, Brennan DJ. Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers. Dis Markers. 2018;2018:1507674.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 67]  [Cited by in RCA: 134]  [Article Influence: 19.1]  [Reference Citation Analysis (0)]
18.  Roeters AE, Oudijk MA, Heydanus R, Bruinse HW. Pregnancy outcome after intra-abdominal bleeding due to placenta percreta at 14 weeks of gestation. Obstet Gynecol. 2007;109:574-576.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 10]  [Cited by in RCA: 11]  [Article Influence: 0.6]  [Reference Citation Analysis (0)]
19.  Taipale P, Orden MR, Berg M, Manninen H, Alafuzoff I. Prenatal diagnosis of placenta accreta and percreta with ultrasonography, color Doppler, and magnetic resonance imaging. Obstet Gynecol. 2004;104:537-540.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 47]  [Cited by in RCA: 36]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
20.  Schwarze A, Nelles I, Krapp M, Friedrich M, Schmidt W, Diedrich K, Axt-Fliedner R. Doppler ultrasound of the uterine artery in the prediction of severe complications during low-risk pregnancies. Arch Gynecol Obstet. 2005;271:46-52.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 32]  [Cited by in RCA: 29]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
21.  Warshak CR, Eskander R, Hull AD, Scioscia AL, Mattrey RF, Benirschke K, Resnik R. Accuracy of ultrasonography and magnetic resonance imaging in the diagnosis of placenta accreta. Obstet Gynecol. 2006;108:573-581.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 325]  [Cited by in RCA: 288]  [Article Influence: 15.2]  [Reference Citation Analysis (0)]
22.  Timmermans S, van Hof AC, Duvekot JJ. Conservative management of abnormally invasive placentation. Obstet Gynecol Surv. 2007;62:529-539.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 183]  [Cited by in RCA: 152]  [Article Influence: 8.4]  [Reference Citation Analysis (0)]
23.  Steins Bisschop CN, Schaap TP, Vogelvang TE, Scholten PC. Invasive placentation and uterus preserving treatment modalities: a systematic review. Arch Gynecol Obstet. 2011;284:491-502.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 63]  [Cited by in RCA: 50]  [Article Influence: 3.6]  [Reference Citation Analysis (0)]
24.  Silver RM, Barbour KD. Placenta accreta spectrum: accreta, increta, and percreta. Obstet Gynecol Clin North Am. 2015;42:381-402.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 103]  [Cited by in RCA: 144]  [Article Influence: 16.0]  [Reference Citation Analysis (0)]
25.  Allen L, Jauniaux E, Hobson S, Papillon-Smith J, Belfort MA; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Nonconservative surgical management. Int J Gynaecol Obstet. 2018;140:281-290.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 136]  [Cited by in RCA: 212]  [Article Influence: 30.3]  [Reference Citation Analysis (0)]
26.  Yin H, Hu R. Outcomes of prophylactic abdominal aortic balloon occlusion in patients with placenta previa accreta: a propensity score matching analysis. BMC Pregnancy Childbirth. 2022;22:502.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 12]  [Reference Citation Analysis (0)]
27.  Liu C, Yang DD, Qu HB, Guo Y, Liu LJ. Efficacy and safety of prophylactic abdominal aortic balloon occlusion versus internal iliac arterial balloon occlusion for placenta accreta spectrum disorder: A systematic review and meta-analysis. Clin Imaging. 2021;78:250-255.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 3]  [Cited by in RCA: 17]  [Article Influence: 4.3]  [Reference Citation Analysis (0)]
28.  Rand T, Patel R, Magerle W, Uberoi R. CIRSE standards of practice on gynaecological and obstetric haemorrhage. CVIR Endovasc. 2020;3:85.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 5]  [Cited by in RCA: 26]  [Article Influence: 5.2]  [Reference Citation Analysis (0)]
29.  Kyozuka H, Yasuda S, Murata T, Sugeno M, Fukuda T, Yamaguchi A, Nomura Y, Fujimori K. Prophylactic resuscitative endovascular balloon occlusion of the aorta use during cesarean hysterectomy for placenta accreta spectrum: a retrospective cohort study. J Matern Fetal Neonatal Med. 2023;36:2232073.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 5]  [Reference Citation Analysis (0)]
30.  Luo R, Wang F, Guan Y, Wan J, Zhang W, Duan Z. A retrospective analysis of the treatment on abdominal aortic balloon occlusion-related thrombosis by continuous low-flow diluted heparin. Medicine (Baltimore). 2019;98:e18446.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 3]  [Cited by in RCA: 4]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
31.  Sanders TK, Stewart JK. Placenta Accreta Spectrum: The Role of Interventional Radiology in Multidisciplinary Management. Semin Intervent Radiol. 2023;40:349-356.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 2]  [Cited by in RCA: 2]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
32.  Gagnon J, Boucher L, Kaufman I, Brown R, Moore A. Iliac artery rupture related to balloon insertion for placenta accreta causing maternal hemorrhage and neonatal compromise. Can J Anaesth. 2013;60:1212-1217.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 19]  [Cited by in RCA: 24]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
33.  Memarian S, Krokidis M, O'Sullivan G, Peynircioglu B, Rossi M, Kashef E. CIRSE Standards of Practice on Arterial Access for Interventions. Cardiovasc Intervent Radiol. 2023;46:302-309.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 5]  [Reference Citation Analysis (0)]
34.  Hunter LA. Exploring the role of uterine artery embolization in the management of postpartum hemorrhage. J Perinat Neonatal Nurs. 2010;24:207-214.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 21]  [Cited by in RCA: 24]  [Article Influence: 1.6]  [Reference Citation Analysis (0)]
35.  Giurazza F, Albano G, Valentino L, Schena E, Capussela T, Di Pasquale MA, Di Pietto F, De Ritis R, Nasti G, Scognamiglio G, Niola R. Predelivery uterine arteries embolization in patients affected by placental implant anomalies. Radiol Med. 2018;123:71-78.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 10]  [Cited by in RCA: 14]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
36.  Hendee WR, Edwards FM. ALARA and an integrated approach to radiation protection. Semin Nucl Med. 1986;16:142-150.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 75]  [Cited by in RCA: 90]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
37.  Dauer LT, Thornton RH, Miller DL, Damilakis J, Dixon RG, Marx MV, Schueler BA, Vañó E, Venkatesan A, Bartal G, Tsetis D, Cardella JF; Society of Interventional Radiology Safety and Health Committee;  Cardiovascular and Interventional Radiology Society of Europe Standards of Practice Committee. Radiation management for interventions using fluoroscopic or computed tomographic guidance during pregnancy: a joint guideline of the Society of Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe with Endorsement by the Canadian Interventional Radiology Association. J Vasc Interv Radiol. 2012;23:19-32.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 72]  [Cited by in RCA: 79]  [Article Influence: 5.6]  [Reference Citation Analysis (0)]
38.  Dai M, Zhang F, Li K, Jin G, Chen Y, Zhang X. The effect of prophylactic balloon occlusion in patients with placenta accreta spectrum: a Bayesian network meta-analysis. Eur Radiol. 2022;32:3297-3308.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 17]  [Cited by in RCA: 16]  [Article Influence: 5.3]  [Reference Citation Analysis (0)]
39.  Abouda SH, Aloui H, Jaouad H, Marzouk SB, Frikha H, Hammami R, Channoufi MB, Maghrebi H. Prophylactic occlusion balloons of both internal iliac arteries in caesarean hysterectomy for placenta accreta spectrum disorder reduces blood loss: A retrospective comparative study. Eur J Obstet Gynecol Reprod Biol X. 2024;22:100310.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 3]  [Reference Citation Analysis (0)]
40.  Narins CR. Access strategies for peripheral arterial intervention. Cardiol J. 2009;16:88-97.  [PubMed]  [DOI]
41.  Huo F, Liang H, Feng Y. Prophylactic temporary abdominal aortic balloon occlusion for patients with pernicious placenta previa: a retrospective study. BMC Anesthesiol. 2021;21:134.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 6]  [Cited by in RCA: 15]  [Article Influence: 3.8]  [Reference Citation Analysis (0)]
42.  Sivan E, Spira M, Achiron R, Rimon U, Golan G, Mazaki-Tovi S, Schiff E. Prophylactic pelvic artery catheterization and embolization in women with placenta accreta: can it prevent cesarean hysterectomy? Am J Perinatol. 2010;27:455-461.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 61]  [Cited by in RCA: 69]  [Article Influence: 4.6]  [Reference Citation Analysis (0)]
43.  Steve Lee K, Sos TA. Brachial Artery Access. Tech Vasc Interv Radiol. 2015;18:87-92.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 10]  [Cited by in RCA: 12]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
44.  Liu J, Xie S, Zhou X, Li Z, Chen J, Han X. The zone II aorta is not a forbidden zone for occlusion in women with morbidly adherent placenta. Arch Gynecol Obstet. 2022;306:977-981.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 5]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
45.  Matsubara S. Aortic balloon occlusion for placenta accreta spectrum: the higher, the better? Arch Gynecol Obstet. 2023;307:1657-1658.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 1]  [Reference Citation Analysis (0)]
46.  Wang Y, Huang G, Jiang T, Han X. Application of abdominal aortic balloon occlusion followed by uterine artery embolization for the treatment of pernicious placenta previa complicated with placenta accreta during cesarean section. J Interv Med. 2019;2:113-117.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 3]  [Cited by in RCA: 3]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
47.  Yang CC, Chou YC, Kuo TN, Liou JY, Cheng HM, Kuo YT. Prophylactic Intraoperative Uterine Artery Embolization During Cesarean Section or Cesarean Hysterectomy in Patients with Abnormal Placentation: A Systematic Review and Meta-Analysis. Cardiovasc Intervent Radiol. 2022;45:488-501.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 2]  [Cited by in RCA: 9]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
48.  Peng Y, Jiang L, Peng C, Wu D, Chen L. The application of prophylactic balloon occlusion of the internal iliac artery for the treatment of placenta accreta spectrum with placenta previa: a retrospective case-control study. BMC Pregnancy Childbirth. 2020;20:349.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 9]  [Cited by in RCA: 23]  [Article Influence: 4.6]  [Reference Citation Analysis (0)]
49.  Zhou X, Sun X, Wang M, Huang L, Xiong W. The effectiveness of prophylactic internal iliac artery balloon occlusion in the treatment of patients with pernicious placenta previa coexisting with placenta accreta. J Matern Fetal Neonatal Med. 2021;34:93-98.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 11]  [Cited by in RCA: 25]  [Article Influence: 4.2]  [Reference Citation Analysis (0)]
50.  Li YT, Yin CS, Chen FM, Chao TC. A useful technique for the control of severe cesarean hemorrhage: report of three cases. Chang Gung Med J. 2002;25:548-552.  [PubMed]  [DOI]
51.  Broekman EA, Versteeg H, Vos LD, Dijksterhuis MG, Papatsonis DN. Temporary balloon occlusion of the internal iliac arteries to prevent massive hemorrhage during cesarean delivery among patients with placenta previa. Int J Gynaecol Obstet. 2015;128:118-121.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 21]  [Cited by in RCA: 24]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
52.  Mei Y, Luo D, Lin Y. Clinical application of prophylactic internal iliac artery balloon occlusion combined with uterine artery embolization in patients with abnormally invasive placenta. J Matern Fetal Neonatal Med. 2018;31:3287-3292.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 5]  [Cited by in RCA: 12]  [Article Influence: 1.5]  [Reference Citation Analysis (0)]
53.  Soyama H, Miyamoto M, Sasa H, Ishibashi H, Yoshida M, Nakatsuka M, Takano M, Furuya K. Effect of routine rapid insertion of Bakri balloon tamponade on reducing hemorrhage from placenta previa during and after cesarean section. Arch Gynecol Obstet. 2017;296:469-474.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 21]  [Cited by in RCA: 25]  [Article Influence: 3.1]  [Reference Citation Analysis (0)]
54.  Fan Y, Gong X, Wang N, Mu K, Feng L, Qiao F, Chen S, Zeng W, Liu H, Wu Y, Zhou Q, Tian Y, Li Q, Yang M, Li F, He M, Beejadhursing R, Deng D. A prospective observational study evaluating the efficacy of prophylactic internal iliac artery balloon catheterization in the management of placenta previa-accreta: A STROBE compliant article. Medicine (Baltimore). 2017;96:e8276.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 27]  [Cited by in RCA: 31]  [Article Influence: 3.9]  [Reference Citation Analysis (0)]
55.  Dai MJ, Jin GX, Lin JH, Zhang Y, Chen YY, Zhang XB. Pre-cesarean prophylactic balloon placement in the internal iliac artery to prevent postpartum hemorrhage among women with pernicious placenta previa. Int J Gynaecol Obstet. 2018;142:315-320.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 11]  [Cited by in RCA: 17]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
56.  Ono Y, Murayama Y, Era S, Matsunaga S, Nagai T, Osada H, Takai Y, Baba K, Takeda S, Seki H. Study of the utility and problems of common iliac artery balloon occlusion for placenta previa with accreta. J Obstet Gynaecol Res. 2018;44:456-462.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 29]  [Cited by in RCA: 34]  [Article Influence: 4.9]  [Reference Citation Analysis (0)]
57.  Picel AC, Wolford B, Cochran RL, Ramos GA, Roberts AC. Prophylactic Internal Iliac Artery Occlusion Balloon Placement to Reduce Operative Blood Loss in Patients with Invasive Placenta. J Vasc Interv Radiol. 2018;29:219-224.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 24]  [Cited by in RCA: 42]  [Article Influence: 5.3]  [Reference Citation Analysis (0)]
58.  Wang YL, Su FM, Zhang HY, Wang F, Zhe RL, Shen XY. Aortic balloon occlusion for controlling intraoperative hemorrhage in patients with placenta previa increta/percreta. J Matern Fetal Neonatal Med. 2017;30:2564-2568.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 15]  [Cited by in RCA: 21]  [Article Influence: 2.6]  [Reference Citation Analysis (0)]
59.  Hussein AM, Dakhly DMR, Raslan AN, Kamel A, Abdel Hafeez A, Moussa M, Hosny AS, Momtaz M. The role of prophylactic internal iliac artery ligation in abnormally invasive placenta undergoing caesarean hysterectomy: a randomized control trial. J Matern Fetal Neonatal Med. 2019;32:3386-3392.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 19]  [Cited by in RCA: 30]  [Article Influence: 4.3]  [Reference Citation Analysis (0)]
60.  Wu Q, Liu Z, Zhao X, Liu C, Wang Y, Chu Q, Wang X, Chen Z. Outcome of Pregnancies After Balloon Occlusion of the Infrarenal Abdominal Aorta During Caesarean in 230 Patients With Placenta Praevia Accreta. Cardiovasc Intervent Radiol. 2016;39:1573-1579.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 62]  [Cited by in RCA: 84]  [Article Influence: 9.3]  [Reference Citation Analysis (0)]
61.  Li K, Zou Y, Sun J, Wen H. Prophylactic balloon occlusion of internal iliac arteries, common iliac arteries and infrarenal abdominal aorta in pregnancies complicated by placenta accreta: a retrospective cohort study. Eur Radiol. 2018;28:4959-4967.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 21]  [Cited by in RCA: 36]  [Article Influence: 5.1]  [Reference Citation Analysis (0)]
62.  Dai M, Jin G, Lin J, Zhang Y, Chen Y, Zhou Q, Zhang X. Control of postpartum hemorrhage in women with placenta accreta spectrum using prophylactic balloon occlusion combined with Pituitrin intra-arterial infusion. Eur Radiol. 2020;30:4524-4533.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 6]  [Cited by in RCA: 15]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
63.  Cho SB, Hong SJ, Lee S, Won JH, Choi HC, Ha JY, Moon JI, Park JK, Park JE, Park SE. Preoperative Prophylactic Balloon-Assisted Occlusion of the Internal Iliac Arteries in the Management of Placenta Increta/Percreta. Medicina (Kaunas). 2020;56:368.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 4]  [Cited by in RCA: 14]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
64.  Sun W, Duan S, Xin G, Xiao J, Hong F, Hong H, Wu Y, Xu Y. Safety and efficacy of preoperative abdominal Aortic balloon occlusion in placenta increta and/or percreta. J Surg Res. 2018;222:75-84.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 23]  [Cited by in RCA: 32]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
65.  Zeng C, Yang M, Ding Y, Yu L, Deng W, Hu Y, Gong X. Preoperative infrarenal abdominal aorta balloon catheter occlusion combined with Bakri tamponade reduced maternal morbidity of placenta increta/percreta. Medicine (Baltimore). 2017;96:e8114.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 17]  [Cited by in RCA: 21]  [Article Influence: 2.6]  [Reference Citation Analysis (0)]
66.  American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 7: Placenta Accreta Spectrum. Obstet Gynecol. 2018;132:e259-e275.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 144]  [Cited by in RCA: 273]  [Article Influence: 39.0]  [Reference Citation Analysis (0)]
67.  Matsubara S, Takahashi H, Takei Y, Nakamura H, Yagisawa T. Prophylactic aortic balloon occlusion for placenta accreta spectrum disorders: Occlusion where? Arch Gynecol Obstet. 2020;302:1553-1554.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 5]  [Cited by in RCA: 7]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
68.  Nankali A, Salari N, Kazeminia M, Mohammadi M, Rasoulinya S, Hosseinian-Far M. The effect prophylactic internal iliac artery balloon occlusion in patients with placenta previa or placental accreta spectrum: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2021;19:40.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 8]  [Cited by in RCA: 20]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]
69.  McGinnis JM, Simula NK, Joseph KS, Ubhi JS. Internal Iliac Artery Balloon Tamponade in Placenta Accreta: Outcomes From the Largest Tertiary Accreta Referral Centre in British Columbia. J Obstet Gynaecol Can. 2019;41:466-472.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 5]  [Cited by in RCA: 13]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
70.  The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37:1-332.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 206]  [Cited by in RCA: 1066]  [Article Influence: 62.7]  [Reference Citation Analysis (0)]